Abstract LB-428: Upregulation of serum amyloid A1 (SAA 1) gene is associated with ulcerative colitis-related colon cancer

2011 ◽  
Author(s):  
Michael W. Schaffer ◽  
Joan C. Smith ◽  
Tanusri Ghosh Roy ◽  
Harold L. Moses ◽  
Samuel E. Adunyah ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Colon Cancer ◽  
Serum Amyloid ◽  
Serum Amyloid A1

Serum Amyloid A, Serum Amyloid A1 and Haptoglobin in pregnant mares and their fetuses after experimental induction of placentitis

2021 ◽  
pp. 106766
Author(s):  
Y. Linhares Boakari ◽  
A. Esteller-Vico ◽  
S. Loux ◽  
H. El-Sheikh Ali ◽  
C. Barbosa Fernandes ◽  
...  
Keyword(s):  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Amyloid A ◽  
Experimental Induction ◽  
Serum Amyloid A1

scholarly journals Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients

Biomedicines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 599
Author(s):  
Víctor Farré-Alins ◽  
Alejandra Palomino-Antolín ◽  
Paloma Narros-Fernández ◽  
Ana Belen Lopez-Rodriguez ◽  
Céline Decouty-Perez ◽  
...  
Keyword(s):  
Injury Severity ◽  
White Blood Cells ◽  
Serum Amyloid ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Important Link ◽  
Tlr4 Mrna ◽  
Serum Amyloid A1

Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical and pathophysiological processes triggered after the trauma is essential. Here, we identified the serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between inflammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC) of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1 levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.

Sa1108 SERUM AMYLOID A PROMOTES INFLAMMATION-ASSOCIATED DAMAGE, MACROPHAGE INFILTRATION AND TUMORIGENESIS IN A MOUSE MODEL OF COLITIS-ASSOCIATED COLON CANCER

2020 ◽  
Vol 158 (6) ◽  
pp. S-278
Author(s):  
Tanja Davis ◽  
Daleen Conradie ◽  
Preetha Shridas ◽  
Marcielle C. de Beer ◽  
Frederick c. de Beer ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Mouse Model ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Macrophage Infiltration ◽  
Amyloid A

scholarly journals P068 - The incidence of adenomatous polyp dysplasia and colon cancer in ulcerative colitis

2009 ◽  
Vol 3 (1) ◽  
pp. S37-S38
Author(s):  
M. Kekilli ◽  
Ü. Dağli ◽  
I. Kalkan ◽  
B. Tunç ◽  
S. Dişibeyaz ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Colon Cancer ◽  
Adenomatous Polyp

scholarly journals Hepatic Expression of Serum Amyloid A1 Is Induced by Traumatic Brain Injury and Modulated by Telmisartan

2015 ◽  
Vol 185 (10) ◽  
pp. 2641-2652 ◽  
Author(s):  
Sonia Villapol ◽  
Dmitry Kryndushkin ◽  
Maria G. Balarezo ◽  
Ashley M. Campbell ◽  
Juan M. Saavedra ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Serum Amyloid ◽  
Hepatic Expression ◽  
Serum Amyloid A1

Ulcerative Colitis and Colon Cancer

1988 ◽  
Vol 17 (4) ◽  
pp. 773-791
Author(s):  
Gerald Isbell ◽  
Bernard Levin
Keyword(s):  
Ulcerative Colitis ◽  
Colon Cancer

scholarly journals Serum Amyloid A1 Induces Classically Activated Macrophages: A Role for Enhanced Fibril Formation

2021 ◽  
Vol 12 ◽  
Author(s):  
Ann-Kathrin Gaiser ◽  
Shanna Bauer ◽  
Stephanie Ruez ◽  
Karlheinz Holzmann ◽  
Marcus Fändrich ◽  
...  
Keyword(s):  
Amyloid Fibrils ◽  
Intervention Strategy ◽  
Serum Amyloid ◽  
Macrophage Phenotype ◽  
Aa Amyloidosis ◽  
Inflammatory Conditions ◽  
Serum Amyloid A1 ◽  
And Function

AA amyloidosis belongs to the group of amyloid diseases which can follow chronic inflammatory conditions of various origin. The disease is characterized by the deposition of insoluble amyloid fibrils formed by serum amyloid A1 (SAA1) leading eventually to organ failure. Macrophages are intimately involved in the fibrillogenesis as well as in the clearance of amyloid fibrils. In vivo, macrophages may occur as classically (M1) or alternatively activated (M2) macrophages. We investigate here how SAA1 might affect the macrophage phenotype and function. Gene microarray analysis revealed upregulation of 64 M1-associated genes by SAA1. M1-like polarization was further confirmed by the expression of the M1-marker MARCO, activation of the NF-κB transcription factor, and secretion of the M1-cytokines TNF-α, IL-6, and MCP-1. Additionally, we demonstrate here that M1-polarized macrophages exhibit enhanced fibrillogenic activity towards SAA1. Based on our data, we propose reconsideration of the currently used cellular amyloidosis models towards an in vitro model employing M1-polarized macrophages. Furthermore, the data suggest macrophage repolarization as potential intervention strategy in AA amyloidosis.

scholarly journals A novel dual-prodrug carried by cyclodextrin inclusion complex for the targeting treatment of colon cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Lin Chen ◽  
Yan Lin ◽  
Zijun Zhang ◽  
Ruisheng Yang ◽  
Xiaosheng Bai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Colon Cancer ◽  
Inclusion Complex ◽  
Tumor Suppression ◽  
Folate Receptor ◽  
Significant Inhibition ◽  
Aminosalicylic Acid ◽  
Anti Inflammatory

Abstract Background There is an obvious correlation between ulcerative colitis and colorectal cancer, and the risk of colorectal cancer in patients with ulcerative colitis is increasing. Therefore, the combination therapy of anti-inflammatory and anti-tumor drugs may show promising to inhibit colon cancer. 5-aminosalicylic acid (5-ASA) with anti-inflammatory function is effective for maintaining remission in patients with ulcerative colitis and may also reduce colorectal cancer risk. Histone deacetylase (HDAC) plays an essential role in the progression of colon cancer. Butyric acid (BA) is a kind of HDAC inhibitor and thus shows tumor suppression to colon cancer. However, the volatile and corrosive nature of BA presents challenges in practical application. In addition, its clinical application is limited due to its non-targeting ability and low bioavailability. We aimed to synthesize a novel dual-prodrug of 5-ASA and BA, referred as BBA, to synergistically inhibit colon cancer. Further, based on the fact that folate receptor (FR) is over-expressed in most solid tumors and it has been identified to be a cancer stem cell surface marker in colon cancer, we took folate as the targeting ligand and used carboxymethyl-β-cyclodextrin (CM-β-CD) to carry BBA and thus prepared a novel inclusion complex of BBA/FA-PEG-CM-β-CD. Results It was found that BBA/FA-PEG-CM-β-CD showed significant inhibition in cell proliferation against colon cancer cells SW620. It showed a pro-longed in vivo circulation and mainly accumulated in tumor tissue. More importantly, BBA/FA-PEG-CM-β-CD gave great tumor suppression effect against nude mice bearing SW620 xenografts. Conclusions Therefore, BBA/FA-PEG-CM-β-CD may have clinical potential in colon cancer therapy. Graphical Abstract

Sign in / Sign up

Export Citation Format

Share Document